Paclitaxel is a frequently employed chemotherapeutic agent for nasopharyngeal carcinoma (NPC) patients, and tumor cell resistance to paclitaxel poses a significant challenge to NPC treatment. This study investigated the impact and potential mechanisms of folate-receptor 1 (FOLR1) on paclitaxel resistance in NPC cells. Levels of FOLR1 in NPC tissues and cells were measured using RT-qPCR. Protein expression was analyzed by Western blot. IC50 of paclitaxel-treated NPC cells was assessed by CCK-8. EdU and Colony formation assay detected cell proliferation. Apoptosis and pyroptosis were evaluated utilizing flow cytometry. Expression and localization of ITCH and FOLR1 were detected by immunofluorescence staining. Interaction between ITCH and FOLR1 was tested by co-immunoprecipitation (Co-IP). The immunoprecipitation assay evaluated FOLR1 ubiquitination levels. An NPC xenograft model was constructed in nude mice. FOLR1 was overexpressed in NPC and correlates with a poor prognosis in NPC patients. Low levels of cell pyroptosis and elevated FOLR1 expression were strongly associated with paclitaxel resistance in NPC. Knockdown of FOLR1 reduced the chemoresistance of 5-8 F/paclitaxel cells to paclitaxel. ITCH was associated with FOLR1 and enhanced its degradation through ubiquitination. ITCH reduced paclitaxel resistance in NPC cells via downregulation of FOLR1. FOLR1 increased resistance to paclitaxel by suppressing pyroptosis in NPC through an NLRP3-dependent mechanism. FOLR1 inhibited pyroptosis by inhibiting the mTOR pathway and promoting autophagy. Lowering FOLR1 expression suppressed tumor growth and boosted paclitaxel sensitivity in mice. FOLR1 plays a significant role in promoting chemoresistance of NPC cells to paclitaxel through NLRP3 signaling.

The study is to investigate differential signaling pathways within the tumor microenvironment across molecular subtypes of breast cancer (BC).

Single-cell RNA (scRNA-seq) sequencing data of BC samples were obtained from the Gene Expression Omnibus database. Cell types were identified using the SingleR package, in conjunction with the analysis of marker genes. Subsequently, Monocle was used for pseudotime analysis of epithelial cells, fibroblasts, and macrophages to characterize their differentiation states. CellChat was employed to study the ligand-receptor interactions among various cell types across different BC molecular subtypes. In addition, we used common bulk RNA sequencing data from The Cancer Genome Atlas to investigate the correlation between key signaling pathway factors identified by scRNA-seq and clinical outcomes.

Inference of copy number variation analysis using T cells revealed significantly elevated copy number variation scores in epithelial cells and fibroblasts. In the communication between epithelial cells and fibroblasts, the ANGPTL pathway is critical in estrogen receptor-positive breast cancer (ER+BC), while the PTN pathway plays a key role in both ER+BC and human epidermal growth factor receptor 2-positive breast cancer (HER2+BC), and the GAS pathway is associated with poor prognosis in triple-negative breast cancer (TNBC). In the interaction between fibroblasts and macrophages, the macrophage subpopulation supporting tumor angiogenesis exhibits significant activity in ER+BC, with the associated SPP1 and GRN pathways strongly influencing tumor progression. The SEMA3 pathway mainly acts through dividing tumor-associated fibroblast clusters across all BC subtypes. When exploring the role of lymphocytes, the PTN pathway also plays a role in HER2+BC, while in TNBC, CXCL and CD70 pathways are significantly involved in immune response modulation.

Our comprehensive analysis of cell-cell communication networks among epithelial cells, fibroblasts, macrophages, and lymphocytes across BC subtypes focuses on ligand-receptor interactions. This study revealed that certain molecules within these networks exhibit significant prognostic value and therapeutic promise.

A direct causal association between inflammatory bowel disease (IBD) and appendiceal neoplasm (AN) is unclear.

Patients with IBD and AN were identified from 1992 to 2023 using bioinformatics and natural language processing tools.

Thirty-one patients were identified. The most common type of AN was appendiceal mucinous neoplasm (83.9 %). Three patients with ulcerative colitis (9.7 %) had recurrence after surgical resection due to peritoneal seeding.

Incidence and recurrence of AN in patients with IBD is low. Further studies to compare AN in patients with and without IBD are needed to determine if IBD predisposes to development of this complication.

EPB41L1-5 is known to maintain cell morphology and signal transduction, with evidence suggesting it can inhibit tumor progression. However, its role in kidney renal clear cell carcinoma (KIRC) is not fully understood. This study evaluated EPB41L1-5's prognostic value in KIRC using bioinformatics methods and validation through qPCR, immunohistochemistry, and cell functional experiments. The results demonstrated a decreased expression of EPB41L in KIRC tissue compared to normal renal tissue, correlating with lower survival rates. Low EPB41L expression was also associated with overall survival in KIRC. Additionally, EPB41L was found to be involved in extracellular matrix regulation, G protein-coupled receptor ligand binding, and multiple immune cell infiltrations. In addition, their elevated methylation levels are associated with poor prognosis in KIRC patients. Overall, EPB41L family is a potential molecular marker for predicting KIRC prognosis, offering insights for therapeutic development.

Giant cell tumor of bone (GCTB) presents considerable complexity in tumor microenvironment (TME) because of its intricate intercellular heterogeneity and the presence of an immunosuppressive milieu. In order to understand the complex gene expression patterns and cell interactions in GCTB, we carried out a thorough investigation using single-cell RNA sequencing (scRNA-seq).

We examined scRNA-seq data from 7091 cells that were collected after surgical removal of GCTB. Following the initial quality control process, 10 separate groups of cells were distinguished, which consisted of dendritic cells, endothelial cells, macrophage cells, mast cells, monocyte cells, neutrophil cells, tumor cells, osteoclast cells, pericyte cells, and T cells. Additional analysis uncovered distinct categories within tumor-associated macrophages (TAMs), CD8+ T cells, and CD4+ T cells. The differentiation mechanisms of TAMs, CD8+ T cells, and CD4+ T cells were explored using pseudo-time trajectory analysis. The CellPhoneDB study revealed the interactions between various cell types within the TME of GCTB.

TAMs have been identified as the main infiltrating cells in GCTB. These TAMs exhibit several subtypes that are characterized by specific marker genes and functional states. The identification of several subgroups within CD8+ T cells that are involved in regulating immunological checkpoints underscores the difficulties encountered when attempting to employ immune checkpoint blockade therapy for GCTB. T cell exhaustion poses a major barrier to the efficacy of antitumor immune responses. Research suggests a strong correlation between TAMs and exhausted T cells (Texs) in the TME. The high number of regulatory T cells (Tregs) highlights the immunosuppressive nature of the immunological environment in GCTB. Significant interactions have been observed between TAMs and tumor cells, highlighting their crucial involvement in immune evasion strategies.

This scRNA-seq study provides a general overview of the different cellular compositions and immune interactions within GCTB. The identified subtypes and communication networks provide valuable information about the immunosuppressive environment of GCTB, laying the foundation for prospective therapeutic approaches targeting specific cell types or interactions.

Dysregulation of apoptosis-related genes (ARGs) may contribute to tumorigenesis and impact patient prognosis, but their specific influence on prognosis and immune characteristics in diffuse large B-cell lymphoma (DLBCL) remains unclear.

Gene expression profiles were collected from GEO datasets GSE10846 (training set; n = 414) and GSE181063 (validation set; n = 1310), totaling 1724 DLBCL samples. Univariate Cox and LASSO Cox regression analyses were performed to identified key ARGs, which were used to construct a risk score model. Patients were stratified into high/low-risk groups using the risk score. Functional enrichment analyses were conducted to explore biological functions and pathways. Immune cell infiltration was assessed using the CIBERSORT algorithm.

39 ARGs were significantly associated with overall survival in DLBCL patients. The risk score model effectively stratified patients into high/low-risk groups with distinct survival outcomes. Consensus clustering revealed distinct molecular subtypes with varying prognoses and biological characteristics. Enrichment analyses indicated that the prognostic genes are involved in critical pathways related to apoptosis and immune responses. High-risk patients exhibited higher immune scores and a distinct tumor immune microenvironment.

Apoptosis-related genes are valuable prognostic biomarkers in DLBCL and are associated with distinct immune characteristics. The risk model may aid in personalized risk assessment and inform treatment strategies. These findings provide insights into potential therapeutic targets by modulating apoptosis and immune responses in DLBCL.

Colorectal cancer (CRC) is a leading cause of cancer-related deaths, with metabolic reprogramming involved in its pathogenesis. Aberrant Arginase 2 (ARG2) expression is linked to malignant progression, but its role in CRC remains unclear.

ARG2 expression in CRC and adjacent tissues was analyzed. In vitro experiments were performed after ARG2 knockdown. Mechanistic investigations focused on epithelial-mesenchymal transition (EMT), PI3K/AKT pathway, immune infiltration, and drug sensitivity.

ARG2 was upregulated in CRC tissues, correlating with poor prognosis. ARG2 knockdown inhibited CRC cell proliferation, migration, and invasion by reducing Zinc Finger E-Box Binding Homeobox 1 (ZEB1), N-cadherin, and MMP2, suppressing EMT. Additionally, ARG2 knockdown significantly inhibited the PI3K/AKT signaling pathway. Immune infiltration analysis revealed high ARG2 expression correlated with reduced activated B cells and macrophages. Drug sensitivity analysis indicated that high ARG2 expression was associated with decreased efficacy of certain chemotherapeutic agents.

ARG2 is an independent prognostic marker for CRC. It promotes CRC progression via regulating EMT and PI3K/AKT, holding potential as a novel diagnostic and therapeutic target.

Interstitial lung abnormalities (ILA) are findings detected on computed tomography (CT) that potentially reflect early stages of interstitial lung disease (ILD). Their prevalence ranges between 3-10% in the general population, with higher rates observed in older individuals and smokers. ILA include bilateral and nonhypostasis-related ground-glass opacities, reticular abnormalities, traction bronchiectasis, lung architectural distortion and honeycombing, affecting more than 5% of a lung zone. The risk of progression to ILD varies between 20-80%, depending on the ILA subtype and associated risk factors. Clinical progression and risk factors include advanced age, nicotine exposure, inhaled noxious substances, thoracic surgical procedures, pneumotoxic treatment and abnormal pulmonary function parameters. Radiologically, fibrotic ILA with subpleural and basal predominance as well as larger extent of lung involvement are significantly associated with increased risk of progression. The clinical management is based on a structured evaluation including high-resolution CT, lung function diagnostics and risk stratification. In the absence of signs of advanced fibrotic changes, individualized follow-up intervals ranging from 6-36 months are recommended, depending on the patient's risk profile. This position paper provides practical recommendations for managing ILA, in line with current international guidelines, while considering new evidence on genetic risk factors, imaging features associated with progression and clinical predictors. The aim is an early identification of high-risk patients and avoidance of unnecessary diagnostic or therapeutic interventions.

Obstructive sleep apnea (OSA) is characterized by recurrent collapses of the upper airway during sleep. Although nasal obstruction has been identified as an independent risk factor for OSA and extensively studied, the relationship between nasal anatomical structures and OSA remains poorly understood. The objective of this study was to determine the relationship between the nasal cross-sectional area (CSA), as measured by magnetic resonance imaging in the supine position, and the presence of OSA, as well as to investigate its correlation with OSA severity.

In this cross-sectional study, a total of 111 participants were enrolled, comprising 88 patients with OSA and 23 healthy controls. All participants underwent polysomnography to determine their apnea-hypopnea index (AHI). Subsequently, MRI scans were performed in the supine position to measure CSA at distances of 1.5, 2, 2.5, 3, 4, 5, and 6 cm posterior to the most anterior point of the nasal cavity. Participants were stratified into groups based on AHI severity, and statistical analyses were conducted to determine the correlation between CSA measurements and the AHI.

Significant intergroup differences were observed in the minimum CSA at the 2.5 and 4.0 cm levels. No difference was found in the sum of nasal CSA at any level. Furthermore, no group differences were found in either nasal cavity volume or surface area. A comparison between healthy individuals and OSA patients revealed that advanced age, a higher body mass index, male sex, and a reduced total minimum nasal cross-sectional area (TMCA) were independent and significant predictors of OSA.

TMCA was identified as a predisposing factor for OSA, but it was not found to be associated with the severity of the condition. Furthermore, long-term, severe OSA may contribute to an enlargement of the CSA.

The role of telehealth use in primary care among rural Medicare Advantage (MA) beneficiaries following Medicare's expanded telehealth coverage during COVID-19 is not well understood. With increasing evidence that provider characteristics influence patient access to telehealth, this study compared receipt of telehealth primary care between rural and nonrural MA beneficiaries by providers' level of telehealth delivery.

Using claims for MA beneficiaries from January 2021 to June 2024, we compared the proportion of primary care visits that were delivered via telehealth between rural and nonrural beneficiaries. We then categorized primary care physician (PCP) groups into quartiles based on the provision of telehealth as a share of total primary care visits. We conducted visit-level generalized linear regression analyses to assess whether differences in telehealth primary care receipt between rural and nonrural beneficiaries varied by PCP telehealth quartile.

PCPs delivering the highest rates of telehealth were significantly more likely to provide primary care via telehealth to rural MA beneficiaries than nonrural ones (4th quartile odds ratio: 1.12, 95% confidence interval: 1.02, 1.22). This finding differed from the overall disparity in telehealth use between rural and nonrural populations, in which rural beneficiaries used less telehealth.

Results showing increased telehealth use among rural MA beneficiaries receiving care from PCPs delivering the highest rates of telehealth may partly stem from unique capabilities among these providers, who are potentially better equipped with tools for implementing telehealth. As such, we provide insight on provider-oriented factors that can bolster telehealth access for rural MA populations.